Hahn Mark W's Form 4 filing

Verona Pharma plc (VRNA) · filed Nov 5, 2024

Accession no.: 0001104659-24-114409
Filed: Nov 5, 2024
Trade date: Nov 1-4, 2024
Filing delay: 4 days
Rule 10b5-1 plan: Checked

Original on SEC EDGAR (opens in a new tab)

This filing lists 2 non-derivative transactions. Open-market sales total $568.8K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
Owner	Relationship to the company
Hahn Mark WCIK 0001408502	Officer (Chief Financial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade date	Security	Transaction	Shares	Price	Value	Shares after	Ownership	Flags
Nov 1, 2024	Ordinary Shares	SSaleDisposed	−48,888	$4.38^F3	−$214,129.44	14,374,520	Direct
Nov 4, 2024	Ordinary Shares	SSaleDisposed	−80,784	$4.39^F4	−$354,641.76	14,293,736	Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

The price reported represents a weighted average price of the ADSs divided by eight (8). The securities were sold in multiple transactions at prices ranging from $4.375 to $4.3825 per Ordinary Share, inclusive (or $35.00 to $35.06 per ADS, inclusive). The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

The price reported represents a weighted average price of the ADSs divided by eight (8). The securities were sold in multiple transactions at prices ranging from $4.375 to $4.4225 per Ordinary Share, inclusive (or $35.00 to $35.38 per ADS, inclusive). The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)